Pfizer’s proposed $43 billion takeover of Seagen Inc. is currently under the microscope of the Federal Trade Commission (FTC). Amidst an industry-wide string of attempted mergers and acquisitions, the FTC has launched an extensive antitrust review of the high-profile deal.
Seagen claimed that both companies have been served a “second request” seeking additional information to fuel the review. Originally, the filing was withdrawn in June, but Pfizer and Seagen then resubmitted it to grant the FTC more time to conduct their initial evaluation.
“We continue to expect that the acquisition of Seagen by Pfizer will be completed in late 2023 or early 2024,” said Seagen in a regulatory filing, reported Reuters.
Yet even this optimistic prediction has been clouded by the scrutiny of the FTC blocking Amgen’s attempted purchase of Horizon Therapeutics for $27.8 billion, leaving investors on edge.
Read more: French Government Criticizes Appointment Of US Economist As Chief Antitrust Advisor
Commenting on the acquisition, Alicia Dubuc of the FTC said: “We recognize the need to examine with particular scrutiny proposed mergers that may result in lessening of competition and higher prices for consumers. We remain diligent in protecting the American public from these potential harms.”
The Pfizer-Seagen deal is being viewed as an indicator of the Federal Trade Commision’s attitude towards mergers and acquisitions amongst biopharmaceutical firms. As investors anxiously await the results of the review, it will likely set a long-term trend across the industry.
Source: Reuters
Featured News
European Music Streaming Firms Rally Against Apple’s Proposed Remedies
May 9, 2024 by
CPI
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI